第11批集采文件发布，创新药ETF天弘（517380）盘中涨超2%，机构：创新药产业向上趋势不变

Market Performance - A-shares and Hong Kong stocks weakened collectively, while the pharmaceutical sector showed active performance, with the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Selected 50 Index (HSSSHID.HK) rising by 0.63% [1] - Within this index, Haoyuan Pharmaceutical increased by over 5%, while WuXi AppTec, Kelun Pharmaceutical, and Ganli Pharmaceutical rose by over 3% [1] - The National Biopharmaceutical Index (399441.SZ) fell by 0.55%, with Ganli Pharmaceutical up nearly 3%, and Rongchang Biopharmaceutical and Zhaoyan New Drug both rising by over 1% [1] ETF Performance - The Tianhong Innovative Drug ETF (517380) saw an intraday increase of over 2%, currently up by 0.7%, with a net inflow of 307 million yuan over the last 10 trading days [1] - The latest circulation size of this ETF is 1.428 billion yuan, with a total circulation of 1.664 billion shares [1] - The Biopharmaceutical ETF (159859) decreased by 0.45%, with a trading volume of 42.47 million yuan and a net inflow of 5.6463 million yuan on the previous trading day [1] Drug Procurement Policy - On September 20, the National Medical Insurance Administration released the 11th batch of centralized drug procurement documents, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [2] - The procurement policy requires selected enterprises to be the primary responsible party for supply assurance and to respond promptly to medical institutions' orders [2] Clinical Trials and Drug Approvals - Watson Bio announced that its subsidiary, in collaboration with several institutions, has applied for clinical trials for a freeze-dried mRNA vaccine for shingles, which has received acceptance notification from the National Medical Products Administration [2] - Sinopharm announced that its self-developed Class 1 biological drug "Tykasimon Antibody Injection" has received acceptance for its market application from the National Medical Products Administration [2] Industry Outlook - Guojin Securities believes the upward trend in the innovative drug industry remains unchanged, with multinational corporations facing patent cliffs and seeking to fill revenue gaps through business development [4] - The second half of the year is expected to see increased global cooperation in innovative drug product licensing, with the innovative drug sector awaiting further business development catalysts [4] - The recent interest rate cut by the Federal Reserve is expected to lower financing costs for biotech companies, encouraging increased R&D investment and generating more orders for CXO companies [4]